Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function
- Registration Number
- NCT07169825
- Lead Sponsor
- M.D. Anderson Cancer Center
- Brief Summary
To determine the dose of Pluvicto therapy absorbed in the tumors and organs of patients whose kidneys and/or bone marrow are not working properly.
- Detailed Description
Primary Objectives
• To determine the personalized radiation dose to tumors and critical organs of participants with compromised renal and / or bone marrow function.
Secondary Objectives
* To compare target radiation doses based on varying SPECT scan duration. Plot the variability in target radiation dose versus scan duration.
* To compare the image quality and dosimetry results when considering the low, high, and both energy peaks of Lu-177.
* To compare target radiation doses based on multiple imaging time points versus a single time point and identify which time point is most suited for this evaluation.
* To compare target radiation doses derived from organ versus voxel dosimetry calculation.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Male
- Target Recruitment
- 25
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA Lu-177 - Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA SPECT -
- Primary Outcome Measures
Name Time Method safety and adverse events (AEs). Through study completion; an average of 1 year Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
MD Anderson Cancer Center🇺🇸Houston, Texas, United StatesGuofan Xu, MDPrincipal Investigator